HK1124761A1 - Gsk-3 inhibitors gsk-3 - Google Patents

Gsk-3 inhibitors gsk-3

Info

Publication number
HK1124761A1
HK1124761A1 HK09101997.2A HK09101997A HK1124761A1 HK 1124761 A1 HK1124761 A1 HK 1124761A1 HK 09101997 A HK09101997 A HK 09101997A HK 1124761 A1 HK1124761 A1 HK 1124761A1
Authority
HK
Hong Kong
Prior art keywords
gsk
inhibitors
inhibitors gsk
Prior art date
Application number
HK09101997.2A
Other languages
English (en)
Inventor
Gil Ana Martinez
Padilla Miguel Medina
Cascon Mercedes Alonso
Huerta Ana Fuertes
Rico Maria Luisa Navarro
Puerto Maria Jose Perez
Morera Ana Castro
Aparicio Ester Martin
Original Assignee
Noscira Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noscira Sa filed Critical Noscira Sa
Publication of HK1124761A1 publication Critical patent/HK1124761A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
HK09101997.2A 2005-07-29 2009-03-03 Gsk-3 inhibitors gsk-3 HK1124761A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05380176A EP1749523A1 (fr) 2005-07-29 2005-07-29 Des inhibiteurs de GSK-3
PCT/EP2006/007520 WO2007017145A2 (fr) 2005-07-29 2006-07-28 Inhibiteurs de la gsk-3

Publications (1)

Publication Number Publication Date
HK1124761A1 true HK1124761A1 (en) 2009-07-24

Family

ID=35445902

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09101997.2A HK1124761A1 (en) 2005-07-29 2009-03-03 Gsk-3 inhibitors gsk-3

Country Status (24)

Country Link
US (1) US8686042B2 (fr)
EP (2) EP1749523A1 (fr)
JP (1) JP5484726B2 (fr)
KR (1) KR101471999B1 (fr)
CN (1) CN101257900B (fr)
AU (1) AU2006278829B2 (fr)
BR (1) BRPI0615968B1 (fr)
CA (1) CA2616451C (fr)
CY (1) CY1119971T1 (fr)
DK (1) DK1919465T3 (fr)
ES (1) ES2661326T3 (fr)
HK (1) HK1124761A1 (fr)
HR (1) HRP20180109T1 (fr)
HU (1) HUE036844T2 (fr)
IL (1) IL189048A (fr)
LT (1) LT1919465T (fr)
NO (1) NO341454B1 (fr)
NZ (1) NZ566380A (fr)
PL (1) PL1919465T3 (fr)
PT (1) PT1919465T (fr)
RU (1) RU2449998C2 (fr)
SI (1) SI1919465T1 (fr)
WO (1) WO2007017145A2 (fr)
ZA (1) ZA200800983B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642598B2 (en) 2006-10-21 2014-02-04 Abbvie Inc. Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
MX2010008706A (es) * 2008-02-06 2010-08-30 Noscira Sa Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
EP2262498A2 (fr) * 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines et pyridines utiles comme inhibiteurs des protéines kinases
CA2720659C (fr) * 2008-04-24 2016-10-18 Abbott Gmbh & Co. Kg Derives de 1-(7-(hexahydropyrrolo[3,4-c]pyrrol-2(1h)-yl)quinolein-4-yl)-3-(pyrazin-2-yl)uree et composes apparentes en tant qu'inhibiteurs de glycogene synthase kinase 3 (gsk-3)
CN104940202B (zh) 2009-06-17 2018-10-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
CA2810954A1 (fr) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Composes heterocycliques et leur utilisation en tant qu'inhibiteurs de la glycogene synthase kinase-3
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2013173206A1 (fr) * 2012-05-14 2013-11-21 University Of Kansas Dérivés de phosphonate pour le traitement de la maladie d'alzheimer
CN108865972B (zh) 2013-03-14 2022-07-29 布里格海姆妇女医院公司 一种细胞培养溶液
PL3068782T3 (pl) 2013-11-13 2018-12-31 Vertex Pharmaceuticals Incorporated Sposoby wytwarzania inhibitorów replikacji wirusów grypy
NZ719729A (en) 2013-11-13 2022-04-29 Vertex Pharma Inhibitors of influenza viruses replication
KR20230019500A (ko) 2014-09-03 2023-02-08 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
WO2017120543A1 (fr) 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production de cellules entéroendocrines différenciées et cellules produisant de l'insuline
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
CN106727556B (zh) * 2016-11-30 2017-10-20 鑫喆喆 一种治疗脑损伤的药物组合物
EP3562827A1 (fr) 2016-12-30 2019-11-06 Frequency Therapeutics, Inc. Composés 1h-pyrrole-2,5-dione et leurs procédés d'utilisation pour induire un auto-renouvellement de cellules de support souches/progénitrices
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
WO2020037326A1 (fr) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions et méthodes pour produire des cellules ciliées par la régulation à la baisse de foxo
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN117186027B (zh) * 2023-09-11 2024-04-19 上海蓝木化工有限公司 一种糖原合酶激酶-3抑制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895625A (en) * 1957-12-27 1962-05-02 Hoechst Ag New benzene-sulphonyl benzyl-ureas and process of preparing them
ES474449A1 (es) * 1978-10-23 1979-05-01 Invest Tecnica Aplicada Procedimiento de obtencion de ureas y tioureas con actividad farmacologica.
EP0131071B1 (fr) * 1983-01-24 1987-05-13 Duphar International Research B.V Dérivés de benzoylurées et les compositions pesticides et pharmaceutiques renfermant ces composés
JPH10182588A (ja) * 1996-10-30 1998-07-07 Ss Pharmaceut Co Ltd 置換ベンジル尿素誘導体及びこれを含有する医薬
US5922767A (en) * 1996-10-30 1999-07-13 Ss Pharmaceutical Co., Ltd. Substituted benzylurea derivatives and medicine containing the same
US6071934A (en) * 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
AU1296699A (en) * 1997-11-07 1999-05-31 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
PE20000942A1 (es) 1998-07-31 2000-09-28 Lilly Co Eli Derivados de amida, carbamato y urea
AU2001245724A1 (en) * 2000-03-14 2001-09-24 Smith Kline Beecham Corporation Il-8 receptor antagonists
US6900041B2 (en) * 2000-10-02 2005-05-31 Reddy Us Therapeutics Inc. Methods and compositions for the treatment of inflammatory diseases
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
JP4613130B2 (ja) * 2002-08-23 2011-01-12 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ベンゾイミダゾールキノリノンおよびそれらの使用
EP1493438A1 (fr) * 2003-07-03 2005-01-05 Bayer HealthCare AG Inhibiteurs du recepteur vanilloide (VR1) dans le traitement de la douleur associée au VIH
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1586318A1 (fr) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiazolidinones comme inhibiteurs de GSK-3

Also Published As

Publication number Publication date
RU2008107733A (ru) 2009-09-10
EP1749523A1 (fr) 2007-02-07
JP5484726B2 (ja) 2014-05-07
EP1919465B1 (fr) 2017-12-27
US8686042B2 (en) 2014-04-01
CN101257900B (zh) 2012-09-12
EP1919465A2 (fr) 2008-05-14
ZA200800983B (en) 2009-07-29
IL189048A0 (en) 2008-08-07
CA2616451C (fr) 2015-01-20
IL189048A (en) 2017-04-30
NO341454B1 (no) 2017-11-13
CA2616451A1 (fr) 2007-02-15
HUE036844T2 (hu) 2018-08-28
DK1919465T3 (en) 2018-02-05
SI1919465T1 (en) 2018-04-30
WO2007017145A2 (fr) 2007-02-15
PL1919465T3 (pl) 2018-06-29
BRPI0615968A2 (pt) 2011-05-31
AU2006278829B2 (en) 2012-03-29
CN101257900A (zh) 2008-09-03
KR20080031440A (ko) 2008-04-08
NZ566380A (en) 2011-01-28
KR101471999B1 (ko) 2014-12-10
AU2006278829A1 (en) 2007-02-15
NO20081052L (no) 2008-02-28
WO2007017145A3 (fr) 2007-04-26
LT1919465T (lt) 2018-04-10
BRPI0615968B1 (pt) 2023-10-03
JP2009502846A (ja) 2009-01-29
RU2449998C2 (ru) 2012-05-10
PT1919465T (pt) 2018-03-07
US20090124686A1 (en) 2009-05-14
HRP20180109T1 (hr) 2018-04-20
CY1119971T1 (el) 2018-12-12
ES2661326T3 (es) 2018-03-28

Similar Documents

Publication Publication Date Title
HK1124761A1 (en) Gsk-3 inhibitors gsk-3
IL178125A0 (en) Gsk-3 inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
HUE038246T2 (hu) Heterobifunkcionális pan-szelektin inhibitorok
SI2383271T1 (sl) Aminokinoloni kot inhibitorji gsk-3
IL190078A0 (en) Kinase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
EP1971595A4 (fr) Inhibiteurs de cetp
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
EP1973889A4 (fr) Inhibiteurs de cetp
ZA200802867B (en) Fap inhibitors
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
EP1906945A4 (fr) Inhibiteurs du vhc
EP1926485A4 (fr) Inhibiteurs du facteur de transcription hif
SI1943243T1 (sl) Inhibotorji kinaz
ZA200805386B (en) MIF inhibitors
IL188850A0 (en) Cathepsin k inhibitors
EP1951053A4 (fr) Inhibiteurs de cetp
GB0515327D0 (en) Comt inhibitors
GB0421355D0 (en) Inhibitors
GB0421356D0 (en) Inhibitors
GB0516967D0 (en) Inhibitors
ZA200711069B (en) HCV inhibitors